Quintiles Opens Expanded Asia-Pacific Headquarters in Singapore

New facility to accommodate increased demand for services from throughout the
region
RESEARCH TRIANGLE PARK, N.C.--(Business Wire)--
To meet the growing demand for its services throughout the Asia-Pacific region,
Quintiles, the only fully integrated biopharmaceutical services company offering
clinical, commercial, consulting and capital solutions worldwide, today
announced the official grand opening of its expanded regional headquarters
facility in Singapore`s Science Park I.

Encompassing three floors of Science Park`s new Cintech IV building, the new
Quintiles regional headquarters facility doubles the size of its previous space
in Singapore and provides additional room for expansion as future demand grows.

"As the world`s biopharmaceutical services leader and the fastest growing
clinical development organization in Asia, we are proud of our history, growth
and long-standing commitment to the entire Asia-Pacific region," said Dennis
Gillings, CBE, Chairman and CEO, Quintiles. "Today`s grand opening of our new
regional headquarters facility here in Singapore is a major milestone for our
organization and this region - a region we`ve been proud to call home for more
than 15 years."

Quintiles is leasing a total of 79,000 square feet (7,300 square meters) of
space in the new Cintech IV building - space capable of accommodating
approximately 550 employees when fully occupied.

"Quintiles` expansion today, to make Singapore its strategic home-base in Asia
to drive regional expansion, represents a strong endorsement of Singapore`s
capabilities in regional clinical trial coordination and research. Coupled with
our capabilities in translational research, pharmaceutical and biotech companies
can leverage Singapore as a one-stop location to carry out through-train drug
discovery and development," said Mr. Gan Kim Yong, Minister for Manpower,
Singapore.

"The Asia-Pacific region and the more than 4,000 professionals we employ here
continue to be an integral and growing force in the global drug development and
commercialization marketplace," said Anand Tharmaratnam, M.D., Senior Vice
President and Head of Clinical Development for Quintiles Asia-Pacific. "Our new
facility provides us with the technology, resources and scalability necessary to
meet the needs of our customers in today`s new healthcare landscape as well as
scale our operations to meet their needs in the future."

In addition to variety of regional and clinical functional groups, the new
facility is also home to one of the region`s most advanced central laboratory
facilities.

The new, 13,000 square foot (1,200 square meters) central laboratory facility
doubles the size of the previous Singapore lab, providing the additional space
necessary to accommodate the increasing demand for new and cutting-edge central
laboratory services in the region.

The expanded lab facility provides a variety of globally harmonized lab services
and plans are already underway to expand these capabilities in the coming months
with the addition of an assay development lab (ADL) and an anatomic pathology
lab. Including the newly expanded Singapore facility, Quintiles has the largest
central laboratory network in the world accredited by the College of American
Pathologists (CAP).

Throughout the Asia-Pacific region, Quintiles has more than 20 offices located
in 14 countries providing an unequaled level of service breadth and depth to its
customers. In Singapore, Quintiles employs approximately 250 employees across a
variety of disciplines.

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company
offering clinical, commercial, consulting and capital solutions worldwide. The
Quintiles network of 23,000 engaged professionals in more than 50 countries
around the globe works with an unwavering commitment to patients, safety and
ethics. Quintiles helps biopharmaceutical companies navigate risk and seize
opportunities in an environment where change is constant. For more information,
please visit www.quintiles.com.

Quintiles
Media Relations:
Kevin Nash, +65 6602 1566
kevin.nash@quintiles.com
or
Investor Relations:
Greg Connors, 919-998-2000
invest@quintiles.com

Copyright Business Wire 2009